

- from the human large intestine. *J Appl Bacteriol* 1988; 65: 241-7.
- 8 Gibson GR, Cummings JH, Macfarlane GT. Use of a three-stage continuous culture system to study the effect of mucin on dissimilatory sulfate reduction and methanogenesis by mixed populations of human gut bacteria. *Appl Environ Microbiol* 1988; 54: 2750-5.
 - 9 Christl SU, Gibson GR, Cummings JH. Role of dietary sulphate in the regulation of methanogenesis in the human large intestine. *Gut* 1992; 33: 1234-8.
 - 10 Oremland RS, Taylor BF. Sulfate reduction and methanogenesis in marine sediments. *Geochimica et Cosmochimica Acta* 1978; 42: 209-14.
 - 11 Kristjansson JK, Schönheit P, Thauer RK. Different K_s values for hydrogen of methanogenic bacteria and sulfate reducing bacteria: an explanation for the apparent inhibition of methanogenesis by sulfate. *Arch Microbiol* 1982; 131: 278-82.
 - 12 Thauer RK, Jungermann K, Decker K. Energy conservation in chemotrophic anaerobic bacteria. *Bacteriol Rev* 1977; 41: 100-80.
 - 13 Florin T, Neale G, Gibson GR, Christl SU, Cummings JH. Metabolism of dietary sulphate: absorption and excretion in humans. *Gut* 1991; 32: 766-73.
 - 14 Strocchi A, Furne JK, Ellis CJ, Levitt MD. Competition for hydrogen by human faecal bacteria: evidence for the predominance of methane producing bacteria. *Gut* 1991; 32: 1498-501.
 - 15 Postgate JR. *The sulphate-reducing bacteria*. 2nd edition. Cambridge: Cambridge University Press. 1984.
 - 16 Florin THJ. Hydrogen sulphide and total acid-volatile sulphide in faeces, determined with a direct spectrophotometric method. *Clin Chim Acta* 1991; 196: 127-34.
 - 17 Strocchi A, Levitt MD. Factors affecting hydrogen production and consumption by human fecal flora. *J Clin Invest* 1992; 89: 1304-11.
 - 18 Florin THJ, Jabbar JA. Factors controlling human bowel metabolism. The effect of bile on methanogenesis. *J Gastroenterol Hepatol* 1992; 7: A21.
 - 19 Miller TL, Wolin MJ. Enumeration of *Methanobrevibacter smithii* in human feces. *Arch Microbiol* 1982; 131: 14-8.
 - 20 Miller TL, Wolin MJ. *Methanosphaera stadtmaniae* gen. nov., sp. nov. a species that forms methane by reducing methanol with hydrogen. *Arch Microbiol* 1985; 141: 116-22.
 - 21 McLeod GM, Wiggins HS. Bile-salts in small intestinal contents after ileal resection and in other malabsorption syndromes. *Lancet* 1968; i: 873-6.
 - 22 Percy Robb IW, Jalan KN, McManus JPA, Sircus W. Effect of ileal resection on bile salt metabolism in patients with ileostomy following proctocolectomy. *Clin Sci* 1971; 41: 371-82.
 - 23 Mekhjian HS, Phillips SF, Hofmann AF. Colonic absorption of unconjugated bile acids. Perfusion studies in man. *Dig Dis Sci* 1979; 7: 545-50.
 - 24 Stadler J, Stern HS, Sing Yeung KA, McGuire V, Furrer R, Marcon N, et al. Effect of high fat consumption on cell proliferation activity of colorectal mucosa and on soluble faecal bile acids. *Gut* 1988; 29: 1326-31.

Thyroid function and interferon treatment in chronic hepatitis C

EDITOR.—We read with much interest the article by Marcellin *et al* (*Gut* 1992; 33: 855-6) about two cases of sustained hypothyroidism induced by recombinant α interferon in patients with chronic hepatitis C. The presence of antithyroid antibodies in both patients suggested an autoimmune cause of the hypothyroidism.¹²

We have recently seen a 51 year old woman with chronic active hepatitis C proved on biopsy examination randomised to receive 3 MU of recombinant interferon alfa 2-b (INTRON-A, Schering-Plough Corporation) subcutaneously three times a week for six months. The patient had no history of thyroid disease and had not received any drug known to be toxic to the thyroid. Serum triiodothyronine, thyroxine, free thyroxine, and thyroxine binding globulin were determined by RIA kits (Farnos Diagnostica Ltd, Turku, Finland); serum thyroid stimulating hormone,

thyroid microsomal antigen autoantibodies, and thyroglobulin autoantibodies were measured by IRMA kits (Biocode, Switzerland). Serum samples were collected before treatment and every month for 12 months thereafter.

A transient reduction in triiodothyronine, thyroxine free thyroxine values started at month 4 and an increase in thyroid stimulating hormone values was recorded (Figure). The patient had no clinical signs of hypothyroidism; thyroid autoantibodies remained negative. On this basis, we suggest a multifactorial cause of thyroid function change induced by recombinant α interferon. In our case, a direct inhibition of thyroid hormone synthesis and secretion, or both by recombinant α interferon could have played a determinant role. This mechanism has been shown by *in vitro* experiments with γ interferon.³⁴

A PICCIOTTO
G VARAGONA
P CIANCIOSI
R FRANCESCHINI
A GARIBALDI
G CELLE

Department of Internal Medicine,
University of Genoa,
Genoa, Italy

- 1 Fentiman IS, Balkwill FR, Thomas BS, Russel MJ, Todd I, Bottazzo GF. An autoimmune aetiology for hypothyroidism following interferon therapy for breast cancer. *Eur J Cancer Clin Oncol* 1988; 24: 1299-1303.
- 2 Fentiman IS, Thomas BS, Balkwill FR, Rubens RD, Hayward JL. Primary hypothyroidism associated with interferon therapy of breast cancer. (Letter). *Lancet* 1985; i: 1166.
- 3 Nagayama Y, Izumi M, Ashizawa K, Kiriyaama T, Yokoyama N, Morita S, et al. Inhibitory effect of interferon-gamma on the response of human thyrocytes to Thyrotropin (TSH) stimulation: relationship between the response to TSH and the expression of DR antigen. *J Clin Endocrinol Metab* 1987; 64: 949-53.
- 4 Ashizawa K, Yamashita S, Nagayama Y, Kimura H, Hirayu H, Izumi M, et al. Interferon-gamma inhibits thyrotropin-induced thyroid peroxidase gene expression in cultured human thyrocytes. *J Clin Endocrinol Metab* 1989; 69: 475-7.

Reply

EDITOR.—We read with interest the comment by Picciotto *et al* on our paper reporting another case of hypothyroidism, probably induced by recombinant interferon alfa 2-b in a patient treated for chronic hepatitis C. No antithyroid antibodies were found and the authors suggest a multifactorial mechanism by which thyroid abnormalities are induced.

We agree that, in the absence of antithyroid antibodies, the role of a direct inhibition of thyroid hormone synthesis and secretion by α interferon, or both, might be considered. Indeed, among 22 patients developing thyroid abnormalities while receiving interferon, we found antithyroid antibodies (anti-thyroglobulin and anti-peroxydase) in only half of them (unpublished data). *Ex vivo* studies of patients' thyroid cells, if considered ethical, might provide pertinent information about the mechanisms of the cell damage induced by interferon in these patients.

P MARCELLIN
M POUTEAU
N COLAS LINHART
B BOK
J-P BENHAMOU

Services d'Hépatologie, de
Médecine Nucléaire et de Biophysique
et Consultation de Médecine,
Hôpital Beaujon,
Clichy, France

Biliary endoprosthesis and common bile duct stones

EDITOR.—The report from Peters *et al* (*Gut* 1992; 33: 1412-5) of a group of patients with bile duct stones treated with a biliary endoprosthesis is of considerable interest. This technique has been used by many centres, provides excellent immediate drainage, and reasonable medium term results – but I wish to sound a note of caution. The justification for using stents as permanent treatment must depend on the results in the long term, indeed can only be assessed by lifetime follow up which no one has yet reported. Our own series with a follow up of 2-5 years was encouraging,¹ but more than half of the patients were still alive (despite being apparently at very high risk initially),¹ and many problems may have occurred subsequently.

The number of patients having stenting for bile duct stones in the King's series seems very high – no fewer than 40 of 146 of a consecutive series, including 27 (18%) as projected permanent treatment. The authors suggest that their low rate of duct clearance reflected their referral practice but referral centres should have special expertise. Of 343 patients with duct stones referred to this unit during the last two years, the clearance rate using standard techniques and mechanical lithotripsy was 94%. Stents were used as 'permanent' treat-




Figure: Triiodothyronine, thyroxine, free thyroxine, and thyroid stimulating hormone behaviour in a patient with chronic hepatitis C treated with 3 MU of IFN alfa 2-b for six months.